Biogen Inc. diskutieren
Biogen Inc.
WKN: 789617 / Symbol: BIIB / Name: Biogen / Aktie / Pharmazeutika / Large Cap /
207,10 €
-0,86 %
Buy Biogen Inc.
Buy Biogen Inc.
Buy Biogen Inc.
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $325.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $325.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $350.00 price target on the stock, up previously from $270.00.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at UBS Group AG from $346.00 to $335.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $325.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at BMO Capital Markets from $357.00 to $347.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $379.00 to $374.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Wells Fargo & Company from $350.00 to $343.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Needham & Company LLC from $323.00 to $305.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at BMO Capital Markets from $347.00 to $336.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Truist Financial Co. from $350.00 to $340.00. They now have a "buy" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Royal Bank of Canada from $354.00 to $357.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $363.00 to $381.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Morgan Stanley from $381.00 to $361.00. They now have an "overweight" rating on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $305.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for BIIB provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Nisource Inc. diskutieren